Saffron Attention Randomized Trial: What the Evidence Says

Quick Answer

Saffron Attention Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Difficulties in accessing healthcare, their high costs, personal preferences, and the perceived safety of medicinal herbs have contributed to the increased usage of herbalism. [Hasheminasab Fatemeh Sadat (2026); evidence level 1]
• Given their popularity, it is crucial to have up-to-date risk and benefit assessments on these herbal products. [Hasheminasab Fatemeh Sadat (2026); evidence level 1]
• In recent years, a growing body of scientific evidence supporting several of these traditional uses has shown the potential of saffron and its main ingredients-crocins, crocetin, safranal, and picrocrocin-as pharmacologically relevant compounds. [Campos Catarina (2026); evidence level 3]
• By integrating evidence from in vitro studies, animal models, and clinical trials, this review critically assesses saffron's potential as a multi-target pharmacological agent and identifies key limitations and future directions for its development within pharmaceutical and integrative medicine frameworks. [Campos Catarina (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For saffron attention randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Hasheminasab Fatemeh Sadat (2026). Adverse Events of Saffron ( Crocus sativus L.): Systematic Review of Current Evidence. DOI: 10.1002/hsr2.72212. PMCID: PMC13121846. PMID: 42057871. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13121846/
• Campos Catarina (2026). From Stigma to Therapy: Pharmacological Insights into Saffron Bioactives for Major Non-Communicable Diseases. DOI: 10.3390/ph19030484. PMCID: PMC13029429. PMID: 41901329. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13029429/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.